1. Home
  2. APLM vs GVH Comparison

APLM vs GVH Comparison

Compare APLM & GVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GVH
  • Stock Information
  • Founded
  • APLM 2016
  • GVH 2016
  • Country
  • APLM United States
  • GVH Australia
  • Employees
  • APLM N/A
  • GVH N/A
  • Industry
  • APLM Blank Checks
  • GVH
  • Sector
  • APLM Finance
  • GVH
  • Exchange
  • APLM Nasdaq
  • GVH Nasdaq
  • Market Cap
  • APLM 6.5M
  • GVH 7.4M
  • IPO Year
  • APLM N/A
  • GVH 2023
  • Fundamental
  • Price
  • APLM $5.68
  • GVH $1.03
  • Analyst Decision
  • APLM Strong Buy
  • GVH
  • Analyst Count
  • APLM 1
  • GVH 0
  • Target Price
  • APLM $200.00
  • GVH N/A
  • AVG Volume (30 Days)
  • APLM 25.0K
  • GVH 1.4M
  • Earning Date
  • APLM 04-03-2025
  • GVH 02-12-2025
  • Dividend Yield
  • APLM N/A
  • GVH N/A
  • EPS Growth
  • APLM N/A
  • GVH 12.04
  • EPS
  • APLM N/A
  • GVH 0.09
  • Revenue
  • APLM $198,000.00
  • GVH $16,540,178.00
  • Revenue This Year
  • APLM $415.15
  • GVH N/A
  • Revenue Next Year
  • APLM N/A
  • GVH N/A
  • P/E Ratio
  • APLM N/A
  • GVH $8.65
  • Revenue Growth
  • APLM N/A
  • GVH N/A
  • 52 Week Low
  • APLM $4.71
  • GVH $0.47
  • 52 Week High
  • APLM $42.00
  • GVH $2.57
  • Technical
  • Relative Strength Index (RSI)
  • APLM 40.12
  • GVH 82.00
  • Support Level
  • APLM $5.90
  • GVH $0.47
  • Resistance Level
  • APLM $6.88
  • GVH $1.08
  • Average True Range (ATR)
  • APLM 0.60
  • GVH 0.11
  • MACD
  • APLM 0.01
  • GVH 0.05
  • Stochastic Oscillator
  • APLM 13.17
  • GVH 70.48

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

Share on Social Networks: